|High / Low (52 weeks)||NOK54.0 / NOK33.1|
|Stock market listing||NO|
|Forecast net cash (NOKm)||111.4|
|Forecast gearing ratio (%)||N/A|
|Sector||Pharmaceutical & healthcare|
* % Relative to local index
Other companies in sector Show
|Y/E Dec||Revenue (NOKm)||EBITDA (NOKm)||PBT (NOKm)||EPS (øre)||P/E (x)||P/CF (x)|
Last updated on 28/02/2017
Photocure announced results for 2016 showing strong growth for the Hexvix/Cysview franchise. Total sales for the product were up 13% to NOK131m, driven by growth in both US sales (up 32% to NOK30.5m) and partner sales (up 14% to NOK61.5m). Total revenue for the period was NOK144m and there was NOK152m in operational spending. The company expects expenses in the US to increase significantly in preparation for the Hexvix/Cysview launch in the surveillance market. We now forecast profitability in 2019 instead of 2018.
Last updated on 27/02/2017
Photocure is a photodynamic therapy company focused on bladder cancer imaging, HPV-related diseases and acne. As its products typically are a combination of a drug and a device, hurdles for generics are typically higher than with other therapeutics.
Last updated on 21/12/2016
|Kjetil Hestdal, CEO|
|Erik Dahl, CFO|
+47 22 06 22 10